Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

The FDA has prioritized reviewing Padcev and Keytruda for MIBC patients ineligible for cisplatin chemotherapy, with a target action date of April 7, 2026. Phase 3 EV-303 trial results showed a 60% ...

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend ...

PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care in cisplatin-ineligible patients with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval in muscle-invasive bladder cancer patients who are eligible to receive ...